Receive The Newest Study Notifications

Medidata (NASDAQ: MDSO) today announced that medical technology business Smith & Nephew (LSE: SN, NYSE: SNN) has consolidated all of its global studies on the Medidata Rave Clinical Cloud. The company expanded its use of Rave clinical solutions and will leverage...

3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40) in patients...

Xeris Pharmaceuticals, Inc. (XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive findings from a Phase 1 study of its novel...

Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has announced that the Trial Steering Committee ("TSC") reviewed safety data from the first...

NIH-funded clinical trial finds starting treatment prior to vision loss unnecessary for most people; close monitoring essential. People with good vision despite having center-involved diabetic macular edema can safely forego immediate treatment of their eye condition...

Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have been awarded a $4.6 million grant from the California Institute for Regenerative Medicine - also known as CIRM - to support a phase I clinical trial of a novel...

Interim Top-Line Results to be Announced in June, 2019 TORONTO and HOUSTON, April 30, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that it has...

Opportunities Are Potentially Being Missed to Improve Healthcare Decision Making —Value in Health, the official journal of ISPOR—the professional society for health economics and outcomes research, announced today the publication of new research showing that...

Company on track to report top-line data in July/August time frame Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the last patient has completed their final visit in the Company's pivotal Phase 3 trial (the ACCORDANCE trial)...

ABX464 advancing into Phase 2b dose-finding trial in ulcerative colitis, to be conducted in 232 patients with moderate to severe disease in up to 150 study sites in >15 countries Study recently fully authorized in Canada as first country, with First Patient in...

Allotex, a Boston based private company developing the TransForm Corneal Allograft (TCA) for the treatment of presbyopia (reading glasses) and hyperopia (far sightedness), is pleased to report that over 50 eyes have been treated in the first phase of its clinical...

3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences has recently dosed its first patient in a Phase 2 clinical trial of the FASN (fatty acid synthase) inhibitor TVB-2640 (Ascletis code: ASC40) in...

Pivotal Registration Clinical Study with XRx-008 and Phase 2b Clinical Study withTMX-049 Planned in 2020 XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat...

A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. The drugs are currently used to treat heart disease and angina, among other...

Patient enrollment and dosing is now complete for International Stem Cell Corporation’s (ISCO) Phase 1 trial testing its ISC-hpNSC neural stem cells — a cellular therapy that offers a new approach for treating Parkinson’s disease. “We are excited to announce the...

Results Demonstrate Safety of CVN424 and Enable Initiation of Phase 2 Study in Patients Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has successfully completed its Phase 1 clinical trial of CVN424, the company’s...

BioVie Inc. (BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of BIV201 (continuous infusion terlipressin) in six patients with refractory...

International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the completion of subject...

Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week Treatment with Mavacamten Demonstrated Reductions in Obstruction and Improvements in Patient...

Neuroblastoma is the most common extracranial solid cancer in children, and patients with high-risk disease are challenging to treat. In a promising development, researchers at Baylor College of Medicine released initial findings from the first two patients treated in...